Abud Tulio B, Di Zazzo Antonio, Kheirkhah Ahmad, Dana Reza
Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.
J Ophthalmic Vis Res. 2017 Jan-Mar;12(1):81-92. doi: 10.4103/2008-322X.200156.
The cornea is the most commonly transplanted tissue in the body. Although corneal grafts generally have high success rates, transplantation onto inflamed and vascularized host beds, or so-called high-risk corneal transplantation, has a high rate of graft rejection. The management of this high-risk corneal transplantation is challenging and involves numerous measures. One of the key measures to prevent graft rejection in these cases is the use of systemic immunosuppressive agents. In this article, we will review the systemic immunosuppressive agents most commonly used for high-risk corneal transplantation, which include corticosteroids, cysclosporine A, tacrolimus, mycophenolate mofetil, and rapamycin. Benefits, risks, and published data on the use of these medications for high-risk corneal transplantation will be detailed. We will also summarize novel immunoregulatory approaches that may be used to prevent graft rejection in high-risk corneal transplantation.
角膜是人体最常移植的组织。尽管角膜移植通常成功率较高,但移植到发炎和血管化的宿主床,即所谓的高危角膜移植,其移植排斥率很高。这种高危角膜移植的管理具有挑战性,涉及众多措施。在这些病例中预防移植排斥的关键措施之一是使用全身性免疫抑制剂。在本文中,我们将回顾高危角膜移植最常用的全身性免疫抑制剂,包括皮质类固醇、环孢素A、他克莫司、霉酚酸酯和雷帕霉素。将详细介绍这些药物用于高危角膜移植的益处、风险及已发表的数据。我们还将总结可用于预防高危角膜移植中移植排斥的新型免疫调节方法。